Search...

### CALCULATORS DRUGS TRIALS **GUIDELINES** USPSTF PUBMED

SUMMARY FULL TEXT LINK

Last updated August 30, 2022

# Management of Anterior Cruciate Ligament Injuries

**Management of Anterior Cruciate Ligament Injuries** 

# Recommendations

HISTORY AND PHYSICAL

▶ A relevant history should be obtained, and a focused musculoskeletal exam of the lower extremities should be performed when assessing for an ACL® injury. (S)

**SURGERY TIMING** 

▶ When surgical treatment is indicated for an acute isolated ACL® tear, early reconstruction is preferred because the risk of additional cartilage and meniscal injury starts to increase within 3 months. (S)

SINGLE OR DOUBLE BUNDLE RECONSTRUCTION ▶ In patients undergoing intraarticular ACL® reconstruction single or double bundle techniques can be considered because measured outcomes are similar. (S)

### **AUTOGRAFT VS ALLOGRAFT** ▶ When performing an ACL® reconstruction, surgeons should consider autograft over allograft to improve patient outcomes and decrease ACL® graft failure rate,

particularly in young and/or active patients. (\$)

**AUTOGRAFT SOURCE** ▶ When performing an ACL® reconstruction with autograft for skeletally mature patients, surgeons may favor BTB® to reduce the risk of graft failure or infection, or hamstring to reduce the risk of anterior or kneeling pain. (M)

### **ACL TRAINING PROGRAMS**

REPAIR VS. RECONSTRUCTION

**ASPIRATION OF THE KNEE** 

**ACL SURGICAL RECONSTRUCTION** 

reconstruction may be considered to improve long term pain and function. (L)

▶ Prophylactic bracing is not a preferred option to prevent ACL® injury. (*L*)

▶ Training programs designed to prevent injury can be used to reduce the risk of primary ACL® injuries in athletes participating in high-risk sports. (M)

ANTEROLATERAL LIGAMENT / LATERAL EXTRAARTICULAR TENODESIS

### function, although long-term outcomes are yet unclear. (M)

▶ ACL® tears indicated for surgery should be treated with ACL® reconstruction rather than repair because of the lower risk of revision surgery. (S)

▶ ALL Reconstruction / LET could be considered when performing hamstring autograft reconstruction in select patients to reduce graft failure and improve short-term

## ▶ In the absence of reliable evidence, it is the opinion of the workgroup that physicians may consider aspirating painful, tense effusions after knee injury. (C)

▶ ACL® reconstruction can be considered in order to lower the risk of future meniscus pathology or procedures, particularly in younger and/or more active patients. ACL®

### **MENISCAL REPAIR**

**COMBINED ACL / MCL TEAR** 

PROPHYLACTIC KNEE BRACING

▶ In patients with ACL® tear and meniscal tear, meniscal preservation should be considered to optimize joint health and function. (L)

### may be considered in select cases. (L)

▶ In patients with combined ACL® and MCL tears, non-operative treatment of the MCL injury results in good patient outcomes, although operative treatment of the MCL

### **RETURN TO SPORT**

▶ Functional evaluation, such as the hop test, may be considered as one factor to determine return to sport after ACL® reconstruction. (*L*)

### RETURN TO ACTIVITY FUNCTIONAL BRACING

Description of Evidence Quality

▶ Functional knee braces are not recommended for routine use in patients who have received isolated primary ACL® reconstruction, as they confer no clinical benefit. (L)

### Overall Strength of Evidence Strength Strong Strong

Recommendation Grading

	Moderate	Evidence from two or more "Moderate" quality studies with consistent findings, or evidence from a single "High" quality
		study for recommending for or against the intervention.
Limited L	Low Strength Evidence or Conflicting Evidence	Evidence from two or more "Low" quality studies with consistent findings or evidence from a single "Moderate" quality
		study recommending for against the intervention or diagnostic or the evidence is insufficient or conflicting and does not
		allow a recommendation for or against the intervention.
Consensus* N	No Evidence	There is no supporting evidence. In the absence of reliable evidence, the guideline development group is making a
		recommendation based on their clinical opinion. Consensus statements are published in a separate, complimentary
		document.

Evidence from two or more "High" quality studies with consistent findings for recommending for or against the intervention.

Title

Overview

ACL: Anterior Cruciate Ligament

• BTB: Bone Patellar Bone

American Academy of Orthopaedic Surgeons

Authoring Organization

Publication Month/Year August 22, 2022

Management of Anterior Cruciate Ligament Injuries

Guideline

External Publication Status

Country of Publication US

**Published** 

Document Type

Orthpaedic surgeons, emergency medicine physicians and other allied providers

Inclusion Criteria

Target Provider Population

Male, Female, Adolescent, Adult, Child

Health Care Settings

Intended Users Athletics coaching, nurse, nurse practitioner, occupational therapist, physical therapist, physician, physician assistant

Scope Assessment and screening, Treatment, Management, Prevention, Rehabilitation

Ambulatory, Emergency care, Outpatient, Operating and recovery room

Diseases/Conditions (MeSH)

Keywords

Source Citation

American Academy of Orthopaedic Surgeons Management of Anterior Cruciate Ligament Injurie EvidenceBased Clinical

View data summaries via the ACL CPG eAppendix 2

ACL injury, Anterior Cruciate Ligament

D016118 - Anterior Cruciate Ligament

Methodology **Number of Source Documents** 342 Literature Search Start Date June 6, 2020

Practice Guidline. www.aaos.org/aclcpg Published 08/22/2022 View background materials via the ACL CPG eAppendix 1

Literature Search End Date

SHOP ADDITIONAL RESOURCES SOLUTIONS **CONTACT US** CART ABOUT **About Guideline Central** Providers & Institutions All Products Contact Form Guidelines Calculators Get the App Submit Your Own Guideline Medical Societies

Careers

Guideline Central Blog

Privacy & Terms

**Testimonials** 

Frequently Asked Questions

August 27, 2021

Payers

Pharma

Partners & Advertisers

© 2023 Guideline Central

Drugs

USPSTF

PubMed

Clinical Trials

Connect: in f

Request Reprints

Advertise With Us





Q

**FEEDBACK**